FLT3 Inhibitor XY0206 clinical trials
Also written XY0206.
How each study uses FLT3 Inhibitor XY0206 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the FLT3 Inhibitor XY0206 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- XY0206
- 4
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Shijiazhuang Yiling Pharmaceutical Co. Ltd (5)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test FLT3 Inhibitor XY0206, phase 3 first.
- Jul 2027A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)Phase 3 · Shijiazhuang Yiling Pharmaceutical Co. Ltd
Studies
Open first, then newest update. How each study uses FLT3 Inhibitor XY0206 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy ParticipantsRecruitingPhase 1Shijiazhuang Yiling Pharmaceutical Co. LtdNCT07162116Written as XY0206
- A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)Not yet recruitingPhase 3Shijiazhuang Yiling Pharmaceutical Co. LtdNCT05876832Written as XY0206
- A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid LeukemiaRecruitingPhase 1Shijiazhuang Yiling Pharmaceutical Co. LtdNCT04471064Written as XY0206
- A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese MenCompletedPhase 1Shijiazhuang Yiling Pharmaceutical Co. LtdNCT06823232Written as [14C]XY0206
- A Study of XY0206 in Subjects With Advanced or Metastatic Solid TumoursStatus unknownPhase 1Shijiazhuang Yiling Pharmaceutical Co. LtdNCT03658070Written as XY0206